CLAIMS

1.- Benzene-sulphonamide derivates having the general formula (I):

(I) 

in which:

X represents a nitro, cyano, halogen group, eventually radioactive .

Y_1 represents a secondary or tertiary amino group, a sulphur or an oxygen

Y_2 represents a -NH group ,a nitrogen or an oxygen ;

Z represents oxygen, sulphur, -N-CN or -CH-NO_2; and

R_1 and R_2, which can be identical or different, represent each independently a linear or ramified alkyl group, saturated or unsaturated with 2 to 12 carbon atoms, an alicyclic group, saturated or unsaturated with 3 to 12 carbon atoms, eventually radioactive, an aryl group, substituted or not by one or several alkyl groups in C_1-C_4, nitro, cyano, trifluoromethyl, carboxy and halogen groups, or an arylalkyl group,

or R_1 and/or R_2 form with Y_1 and/or Y_2 a 5 to 7 membered heterocyclic group, saturated or unsaturated

with the exception of derivatives for which X is a nitro group, . Y_1 represents a secondary amine group (-NH-), Y_2 represents a -NH group, Z an oxygen, R_2, an isopropyl and R_1 an element selected in a group constituted of (m-toluyl, phenyl and cyclooctyl) and with the exception of N-[(2-CYCLOOCTYLAMiNO-5-CYANOBeNZeNe)SULFONYL] N'-isopropyl urea. ;

2.- Derivate according to claim 1, characterized in that X represents nitro, cyano, bromo, iodine group.

3.- Derivate according to one or the other claims 1 and 2, characterized in that Y_1 represents a -NH group and Y_2 represents a -NH group or an oxygen atom.

4.- Derivate according to any of claims 1 to 3, characterized in that R_1 and R_2 represent each independently an ethyl, butyl, tert-butyl, propyl, isopropyl, pentyl, hexyl, heptyl, octyl, decyl, amyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclododecyl, 2-cyclohexenyl, m-toluyl, o-toluyl, p-toluyl, phenyl, allyl, adamantyl, norbornyl; caproyl, 3-carboxyphenyl, 2,3-dimethylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2,4,6-trimethylphenyl, furfuryl, benzyl or 1-phenylthyl group.

5.- Derivate according to one or the other claims 1 and 2, characterized in that R_2 and Y_2 form a homopiperidin group.

6.- Derivate according to one or the other claims 1 and 2, characterized in that R_1 and Y_1 form a morpholin or homopiperidin group.

7.- Derivate according to any of claims 1 to 6, characterized in that it is constituted by a salt chosen into the group formed by sodium salts, the potassic salts and the amino acid salts such as lysine, arginine.

8.- Derivate according to any of claims 1 to 7, characterized in that it is chosen in a group having:

N-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]N'-tert-butyl urea,

N-cyano-N'-[(2-metatoluylamino-5-nitrobenzene)sulfonyl]homopiperidinoamidine,

N-[(2-cycloheptylamino-5-nitrobenzene)sulfonyl]N'-cyclohexyl thiourea, and

N-[(cyclohexen-2-yl)-5-iodobenzene)sulfonyl]N'-pentyl urea.

9.- Pharmaceutical composition, characterized in that it includes a benzene sulphonamide derivate according to any of claims 1 to 8 in

mixture with an acceptable pharmaceutical excipient and eventually other therapeutic agents.

10.- Use of a derivate according to any of claims 1 to 8, for the production of a medicament for the treatment and/or the prevention of the illnesses involving the thromboxan A2 , such as for cardio-vascular and blood , pulmonary, reproduction and renal use.

11.- Use of a derivate according to any of claims 1 to 8, as radiolabelled pharmacological tool of the thromboxan A2 receptors.

Add a1